Published in:
Open Access
01-12-2022 | Computed Tomography | Research
Plasma sRAGE levels strongly associate with centrilobular emphysema assessed by HRCT scans
Authors:
Frank Klont, Peter Horvatovich, Russell P. Bowler, Eva van Rikxoort, Jean-Paul Charbonnier, Marcel Kwiatkowski, David A. Lynch, Stephen Humphries, Rainer Bischoff, Nick H. T. ten Hacken, Simon D. Pouwels
Published in:
Respiratory Research
|
Issue 1/2022
Login to get access
Abstract
Background
There is a strong need for biomarkers to better characterize individuals with COPD and to take into account the heterogeneity of COPD. The blood protein sRAGE has been put forward as promising biomarker for COPD in general and emphysema in particular. Here, we measured plasma sRAGE levels using quantitative LC–MS and assessed whether the plasma sRAGE levels associate with (changes in) lung function, radiological emphysema parameters, and radiological subtypes of emphysema.
Methods
Three hundred and twenty-four COPD patients (mean FEV1: 63%predicted) and 185 healthy controls from the COPDGene study were selected. Plasma sRAGE was measured by immunoprecipitation in 96-well plate methodology to enrich sRAGE, followed by targeted quantitative liquid chromatography-mass spectrometry. Spirometry and HRCT scans (inspiration and expiration) with a 5-year follow-up were used; both subjected to high quality control standards.
Results
Lower sRAGE values significantly associated with the presence of COPD, the severity of airflow obstruction, the severity of emphysema on HRCT, the heterogeneous distribution of emphysema, centrilobular emphysema, and 5-year progression of emphysema. However, sRAGE values did not associate with airway wall thickness or paraseptal emphysema.
Conclusions
Rather than being a general COPD biomarker, sRAGE is especially a promising biomarker for centrilobular emphysema. Follow-up studies should elucidate whether sRAGE can be used as a biomarker for other COPD phenotypes as well.